A phase I/II, partially randomised, open-labelled study of visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids Not provided at time of registration

• Country Austria, Belgium, Bulgaria, Canada, Germany, Netherlands, United States
• organs None
• Specialty None